FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to a method of treating pain. That is ensured by using a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist as an analgesic action for treating pain, wherein said antagonist is GM-CSF-specific antibody.
EFFECT: use of the given invention enables using a granulocyte-macrophage colony-stimulating factor antagonist for treating pain not associated with inflammation.
5 cl, 6 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| CHIMERIC PROTEIN COMPOSED OF AN NGF ANTAGONIST DOMAIN AND A TNFΑ ANTAGONIST DOMAIN | 2015 |
|
RU2788122C2 |
| ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| METHODS OF PREVENTING AND TREATING HEART DISEASES | 2018 |
|
RU2830232C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
